AstraZeneca Pharma India Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 28.7% YoY

On August 10, 2026, AstraZeneca Pharma India Limited released its unaudited financial results for the quarter ending June 30, 2026, as per the exchange filings.  

The company reported a total income of ₹692.02 crore and a net profit of ₹37.93 crore for the quarter ended June 30, 2026. 

AstraZeneca Pharma India Q1 FY27 Earnings Results 

For the quarter ended June 30, 2026, the total income of AstraZeneca Pharma India Limited was ₹692.02 crore. This reflects a 28.7% increase compared to the income of ₹537.55 crore recorded in the same quarter a year ago.  

When compared to the preceding quarter ended March 31, 2026, where the total income was ₹584.56 crore, the company reported an increase of 18.4%. 

The net profit, or Profit After Tax (PAT), for the June 2026 quarter stood at ₹37.93 crore. This figure represents a 32.1% decline on a year-over-year basis from the ₹55.83 crore reported in the June 2025 quarter.  

Furthermore, the net profit decreased by 15.5% on a quarter over quarter basis from the ₹44.88 crore recorded in the quarter ended March 31, 2026. 

Annual Financial Data for FY26 

The company also provided data regarding its financial performance for the full financial year 2026. The total income for FY26 reached ₹2,304.07 crore. During the same period, the net profit of the organisation was recorded at ₹187.52 crore. 

Board Changes and Management 

The board approved the appointment of Mr. Arun Krishna as an Additional Director (Non-Executive) effective August 17, 2026. He currently serves as the Asia Area Vice President for the broader international organization. 

Consequent to her appointment to a regional corporate role, Ms. Bhavana Agrawal resigned as Chief Financial Officer. The board approved her designation change from Executive Director to Non-Executive Director effective September 1, 2026. 

Therapy Segments Performance 

The core oncology division demonstrated strong commercial performance, generating a segment revenue of ₹464.90 crore. The biopharmaceuticals segment followed as the second largest driver, contributing a revenue of ₹161.90 crore. 

The rare diseases segment generated a minor but rapidly growing revenue contribution of ₹14.40 crore. The company operates strictly under a single reportable operating business segment identified nationally as Healthcare. 

Strategic Alliances and Milestones 

AstraZeneca signed an agreement with the Government of Telangana to introduce AI-enabled lung cancer screening solutions. This clinical program will facilitate early triage across 20 public healthcare facilities spanning urban and rural settings. 

The company also secured vital regulatory approvals for specialized formulations including Acalabrutinib and Trastuzumab deruxtecan. These milestones expand access to innovative treatments for untreated chronic lymphocytic leukaemia and breast cancer. 

Read More: Titan Q1 FY27 Results: Net Profit Rises 63% to ₹1,777 Crore, Revenue Up 40%! 

AstraZeneca Pharma India Share Price Performance 

As of August 10, 2026, at 3:30 PM, AstraZeneca Pharma India share price on NSE was closed at ₹8,090.00, down by 1.23% from the previous closing price. 

Conclusion 

AstraZeneca Pharma India Limited reported a total income of ₹692.02 crore and a net profit of ₹37.93 crore for the June 2026 quarter. FY26 performance figures indicate a total income of ₹2,304.07 crore and net profit of ₹187.52 crore. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.